Maximum quantity allowed is 999
请选择数量
CAS RN: 700874-72-2 | 产品编码: G0639
Galunisertib
×
![]()
×
| 产品编码 | G0639 |
纯度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式/分子量 | C__2__2H__1__9N__5O = 369.43 |
| 外观与形状（20°C） | 固体 |
| 储存温度
|
冷藏 (0-10°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| 包装和容器
|
100MG-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 700874-72-2 |
| Reaxys-RN | 14275134 |
| MDL编号 | MFCD12923319 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 246.0 to 250.0 °C |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 248 °C |
GHS
相关法规
运输信息
| HS编码* | 2933.49-000 |
应用
Galunisertib: An Oral and Selective TGF-β Receptor Type I (TGF-βR type I) Kinase Inhibitor
Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. It has been reported that TGF-β plays an important role in tumorigenesis and migration of cancer cells.1) Galunisertib (LY2157299 monohydrate) is an oral and selective TGF-β receptor type I (TGF-βR type I) kinase inhibitor, and it has been used to study the role of TGF-β signaling in chemotherapy-induced expansion of cancer stem-like cells.2,3) (The product is for research use only.)
References
- 1) TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- 2) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
- 3) Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。